ライフサイエンスコーパス: systemic mastocytosis

1 nophilia that is indicative of an underlying systemic mastocytosis.

2 ges in the peripheral blood of patients with systemic mastocytosis.

3 lls, and monocytes in patients with indolent systemic mastocytosis.

4 s of both soluble receptors are increased in systemic mastocytosis.

5 iple serial time points in two patients with systemic mastocytosis.

6 retrospectively reviewed in 27 patients with systemic mastocytosis.

7 ngs at CT and US are common in patients with systemic mastocytosis.

8 assifications predicted survival outcomes in systemic mastocytosis.

9 s in bone marrow mast cells in patients with systemic mastocytosis.

10 ocytosis (ISM) is the most prevalent form of systemic mastocytosis.

11 of clonal mast cell disease (cMCD) including systemic mastocytosis.

12 ans is elevated manifold in individuals with systemic mastocytosis.

13 mpare the levels with those in patients with systemic mastocytosis.

14 s identified several putative biomarkers for systemic mastocytosis.

15 M-3 and galectin-9 are increased in advanced systemic mastocytosis.

16 d PDGF receptor-beta as novel biomarkers for systemic mastocytosis.

17 d emerging new treatment options in advanced systemic mastocytosis.

18 severely symptomatic indolent or smouldering systemic mastocytosis.

19 e cohort of 164 adult patients with indolent systemic mastocytosis.

20 r adult patients with cutaneous and indolent systemic mastocytosis.

21 , are found in the majority of patients with systemic mastocytosis.

22 merits of conventional drugs for aggressive systemic mastocytosis.

23 mase activity in serum of most subjects with systemic mastocytosis.

24 multifocal mast-cell aggregates observed in systemic mastocytosis.

25 imary efficacy population; 16 had aggressive systemic mastocytosis, 57 had systemic mastocytosis with

26 In 116 patients with systemic mastocytosis (89 patients with advSM fulfilling

27 ic progenitors and are clonally increased in systemic mastocytosis, a disease associated with point m

28 ed 18-75 years) with indolent or smouldering systemic mastocytosis, according to WHO classification o

29 emia (MCL) is a very rare form of aggressive systemic mastocytosis accounting for < 1% of all mastocy

30 nistration in 2021 for treatment of advanced systemic mastocytosis (AdvSM) and by the European Medici

31 Advanced systemic mastocytosis (AdvSM) is a rare hematologic neop

32 Advanced systemic mastocytosis (AdvSM) is a rare, KIT D816V-drive

33 Advanced systemic mastocytosis (advSM) is characterized by presen

34 In advanced systemic mastocytosis (advSM), disease evolution is ofte

35 rease the power of our analysis for advanced systemic mastocytosis (advSM), we pooled our cohort with

36 rin and cladribine in patients with advanced systemic mastocytosis (AdvSM).

37 es in patients with nonadvanced and advanced systemic mastocytosis (AdvSM).

38 cluded patients with cutaneous or non-severe systemic mastocytosis after a protocol amendment.

39 We included 21 adults with systemic mastocytosis and 18 healthy controls.

40 e marrow biopsies from 9 of 10 patients with systemic mastocytosis and activating c-KIT mutations.

41 o promiscuous signaling via oncogenic KIT in systemic mastocytosis and acute myelogenous leukemia are

42 ation loop, most commonly D816V, are seen in systemic mastocytosis and acute myelogenous leukemia.

43 ociated with poor prognosis in patients with systemic mastocytosis and acute myeloid leukemia (AML).

44 astocytosis is further divided into indolent systemic mastocytosis and advanced systemic mastocytosis

45 neation of well defined prognostic groups in systemic mastocytosis and clarification of the merits of

46 a spectrum of clinical conditions, including systemic mastocytosis and cutaneous mastocytosis, mast c

47 se could be distinguished from patients with systemic mastocytosis and eosinophilia by their clinical

48 ical community for a few conditions, such as systemic mastocytosis and eosinophilic esophagitis.

49 ional Prognostic Scoring System for advanced systemic mastocytosis and GPSM-OS model for OS emerged a

50 rum of patients with different categories of systemic mastocytosis and healthy controls and correlate

51 clonal disorders cutaneous mastocytosis and systemic mastocytosis and its variants, including aggres

52 mastocytosis variants, including aggressive systemic mastocytosis and mast cell leukemia.

53 The patient with systemic mastocytosis and MDS carried both mutated U2AF3

54 the work-up for clonal MC disorders such as systemic mastocytosis and monoclonal MC activation syndr

55 Systemic mastocytosis and senior age are major, unmodifi

56 of other checkpoint molecules are altered in systemic mastocytosis and whether these proteins are exp

57 (monoclonal mast cell activation syndrome or systemic mastocytosis) and thus candidates for a bone ma

58 ns in adults with Hymenoptera venom allergy, systemic mastocytosis, and idiopathic anaphylaxis.

59 des the disease into cutaneous mastocytosis, systemic mastocytosis, and localized mast cell tumors.

60 codon D816 that are typically found in AML, systemic mastocytosis, and seminoma are insensitive to i

61 The symptoms of systemic mastocytosis are due to the pathologic accumula

62 Although the findings in patients with systemic mastocytosis are not specific to the disease, t

63 entation of DCM, including 4 with aggressive systemic mastocytosis (ASM) and 29 with DCM.

64 mited treatment options exist for aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL)

65 Aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL)

66 evelop a disease similar to human aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL)

67 nd the survival time of mice with aggressive systemic mastocytosis (ASM).

68 Prognosis in systemic mastocytosis associated with another myeloid ma

69 re remains no effective curative therapy for systemic mastocytosis associated with KITD816V.

70 lling study based on patients diagnosed with systemic mastocytosis between March 1, 1983, and Oct 11,

71 odels have been proposed in recent years for systemic mastocytosis but have not been directly compare

72 seful adjunct in helping identify those with systemic mastocytosis but not monoclonal mast cell activ

73 cribed in approximately 29% of patients with systemic mastocytosis, but their pathogenetic or treatme

74 owed some capacity to predict OS in advanced systemic mastocytosis (C-index 0.72 [0.66-0.78], vs 0.64

75 isting models), particularly in non-advanced systemic mastocytosis (C-index 0.85 [0.76-0.92], within

76 FS score was an accurate predictor of PFS in systemic mastocytosis (C-index 0.90 [95% CI 0.87-0.93],

77 clinicopathologic features of a patient with systemic mastocytosis caused by a de novo germline KIT K

78 Advanced systemic mastocytosis comprises rare hematologic neoplas

79 for the discovery of novel biomarkers in the systemic mastocytosis diagnostic sphere.

80 which enrolled 33 adults with cutaneous and systemic mastocytosis found 4 weeks of treatment with th

81 Patients with advanced systemic mastocytosis have a median survival of 3.5 year

82 Gastrointestinal manifestations of systemic mastocytosis have been previously studied in sm

83 ular understanding of the pathophysiology of systemic mastocytosis have provided new therapeutic cons

84 dhood-onset DCM, the disease can progress to systemic mastocytosis; in others, it resolves spontaneou

85 sed prevalence of HalphaT in all subtypes of systemic mastocytosis (including advSM) is suggestive of

86 ons are available for patients with advanced systemic mastocytosis, including allogeneic hematopoieti

87 ides an update on prognosis and treatment of systemic mastocytosis, including investigational drug th

88 in showed efficacy in patients with advanced systemic mastocytosis, including the highly fatal varian

89 Indolent systemic mastocytosis, including the subvariant of smoul

90 Systemic mastocytosis is a clonal disorder of mast cells

91 Systemic mastocytosis is a clonal disorder of the mast c

92 Systemic mastocytosis is a clonal mast cell (MC) disease

93 Systemic mastocytosis is a disease of mast cell prolifer

94 Systemic mastocytosis is a hematological disease in whic

95 Systemic mastocytosis is a neoplastic disease of mast ce

96 Systemic mastocytosis is characterized by expansion of c

97 clinical parameters, and organ involvement, systemic mastocytosis is further divided into indolent s

98 sis, including the subvariant of smouldering systemic mastocytosis, is a lifelong condition associate

99 individuals with HalphaT (n = 33), indolent systemic mastocytosis (ISM) (n = 52), and ISM + HalphaT

100 s of individuals with HaT (n = 33), indolent systemic mastocytosis (ISM) (n = 52), and ISM + HaT (n =

101 Clinical manifestations of indolent systemic mastocytosis (ISM) comprise mediator-related sy

102 Risk indicators of indolent systemic mastocytosis (ISM) in adults with clinical susp

103 Indolent systemic mastocytosis (ISM) is a rare disease characteri

104 Indolent systemic mastocytosis (ISM) is characterized by patholog

105 Indolent systemic mastocytosis (ISM) is the most prevalent form o

106 Indolent systemic mastocytosis (ISM) patients have a normal life

107 ion is present in a subset of adult indolent systemic mastocytosis (ISM) patients in association with

108 Indolent systemic mastocytosis (ISM) without skin lesions (ISMs(-

109 ients with a confirmed diagnosis of indolent systemic mastocytosis (ISM), and 23 healthy controls.

110 s occur frequently in patients with indolent systemic mastocytosis (ISM), even before 50 years of age

111 In indolent systemic mastocytosis (ISM), several risk factors of dis

112 in cutaneous mastocytosis (CM) and indolent systemic mastocytosis (ISM), whereas in advanced SM (adv

113 Two of these individuals had indolent systemic mastocytosis (ISM).

114 iopsy in patients suspected to have indolent systemic mastocytosis (ISM).

115 imilar regardless of the subtype of advanced systemic mastocytosis, KIT mutation status, or exposure

116 us mastocytosis) is infrequent in adults and systemic mastocytosis may be broadly classified as an in

117 tosis and its variants, including aggressive systemic mastocytosis, MC leukemia, and MC sarcoma.

118 rker study on blood from twenty individuals (systemic mastocytosis: n = 12, controls: n = 8), which w

119 Patients with systemic mastocytosis often have symptoms of mast cell a

120 survival (PFS) and overall survival (OS) in systemic mastocytosis on the basis of all currently avai

121 those with diffuse cutaneous (P < .0001) and systemic mastocytosis (P < .0001) and in all 3 categorie

122 one marrow mast cell burden in patients with systemic mastocytosis (P < .0001).

123 arkers and eventually therapeutic targets in systemic mastocytosis, particularly in advanced forms.

124 ls of TIM-3 and galectin-9 were increased in systemic mastocytosis, particularly in advanced subtypes

125 nd LYN kinases that are involved in indolent systemic mastocytosis pathogenesis.

126 In the indolent systemic mastocytosis population, all mast cell load mar

127 The Perceptions Realities and Insights on Systemic Mastocytosis (PRISM) survey queried patient and

128 use for acute myeloid leukemia and advanced systemic mastocytosis, reduced keratin aggregation by 40

129 treatment outcome in 342 adult patients with systemic mastocytosis seen at our institution.

130 tyrosine kinase activity are associated with systemic mastocytosis (SM) and chronic eosinophilic leuk

131 V mutation is found in >80% of patients with systemic mastocytosis (SM) and is key to neoplastic mast

132 ease is divided into cutaneous mastocytosis, systemic mastocytosis (SM) and mast cell sarcoma.

133 ents with clonal mast cell disorders (cMCD), systemic mastocytosis (SM) and monoclonal mast cell acti

134 ontributing to the clinical heterogeneity of systemic mastocytosis (SM) and to suboptimal responses t

135 Cohorts with systemic mastocytosis (SM) and venom as well as idiopath

136 hat a great majority (>90%) of patients with systemic mastocytosis (SM) carry a common genetic lesion

137 mic mastocytosis (WDSM) is a rare variant of systemic mastocytosis (SM) characterized by bone marrow

138 Systemic mastocytosis (SM) encompasses a heterogeneous g

139 Systemic mastocytosis (SM) has greatly benefited from th

140 f bone disease are frequent in patients with systemic mastocytosis (SM) in association with the prese

141 czema, 124.4 (SD 43.2) in five patients with systemic mastocytosis (SM) in comparison with autopsy sk

142 Systemic mastocytosis (SM) is a clonal mast cell disease

143 Systemic mastocytosis (SM) is a heterogeneous disease ch

144 Systemic mastocytosis (SM) is a heterogeneous disease ch

145 Systemic mastocytosis (SM) is a heterogeneous group of m

146 Systemic mastocytosis (SM) is a KIT-driven hematopoietic

147 Systemic mastocytosis (SM) is characterized by abnormal

148 Systemic mastocytosis (SM) is characterized by accumulat

149 Systemic mastocytosis (SM) is defined by the expansion a

150 Clinical phenotype in systemic mastocytosis (SM) is markedly variable, which c

151 Systemic mastocytosis (SM) may be associated with hymeno

152 Systemic mastocytosis (SM) may or may not present with c

153 Patients with systemic mastocytosis (SM) may suffer from mast cell (MC

154 Indolent systemic mastocytosis (SM) patients have a varied clinic

155 Current diagnostic algorithms for systemic mastocytosis (SM) rely on the detection of KITD

156 Timely diagnosis of systemic mastocytosis (SM) remains challenging because o

157 Advanced systemic mastocytosis (SM), a fatal hematopoietic malign

158 ith hypereosinophilic syndrome (HES), 8 with systemic mastocytosis (SM), and 6 with chronic neutrophi

159 sser extent blood eosinophilia, is common in systemic mastocytosis (SM), but its significance remains

160 In systemic mastocytosis (SM), clinical problems arise from

161 e KIT play a key role in the pathogenesis of systemic mastocytosis (SM), gastrointestinal stromal tum

162 with cutaneous mastocytosis or with indolent systemic mastocytosis (SM), various KIT-activating mutat

163 ses of acute myelogenous leukemia (AML), and systemic mastocytosis (SM).

164 of a small number of patients with advanced systemic mastocytosis (SM).

165 bone marrow (BM) investigation in suspected systemic mastocytosis (SM).

166 c mast cells (MCs) in patients with advanced systemic mastocytosis (SM).

167 6V is present in a majority of patients with systemic mastocytosis (SM).

168 observed in acute myeloid leukemia (AML) and systemic mastocytosis (SM); however, unlike the KIT juxt

169 skin: MIS) and/or involving internal organs (systemic mastocytosis: SM).

170 found to correlate with other biomarkers of systemic mastocytosis, such as serum tryptase and KIT D8

171 d shares more clinicopathologic aspects with systemic mastocytosis than with acute myeloid leukemia.

172 ber of aggressive and nonaggressive cases of systemic mastocytosis, that in contrast to the oncogenic

173 ment in patients with cutaneous and indolent systemic mastocytosis, the Mastocytosis Quality of Life

174 In subjects with systemic mastocytosis, the number of mast cells is eleva

175 Plasma sCD25 levels were elevated in systemic mastocytosis; the highest levels were associate

176 lood in both healthy subjects and those with systemic mastocytosis under nonacute conditions.

177 rognosis was not as good in the WHO indolent systemic mastocytosis variant of smoldering mastocytosis

178 indolent systemic mastocytosis and advanced systemic mastocytosis variants, including aggressive sys

179 Life expectancy in indolent systemic mastocytosis was not significantly different th

180 Well-differentiated systemic mastocytosis (WDSM) is a rare myeloid neoplasm

181 Well-differentiated systemic mastocytosis (WDSM) is a rare variant of system

182 n abdominal imaging findings associated with systemic mastocytosis were hepatosplenomegaly, retroperi

183 Bone marrow biopsies from patients with systemic mastocytosis were stained to confirm expression

184 bility, 36 patients with either cutaneous or systemic mastocytosis were studied for association with

185 Samples from a patient with indolent systemic mastocytosis were used for this study.

186 ic bone marrow mast cells from patients with systemic mastocytosis while sparing other hematopoietic

187 ent with urticaria pigmentosa and aggressive systemic mastocytosis, whose pathologic mast cells are c

188 In patients with indolent systemic mastocytosis with a history of Hymenoptera veno

189 cutaneous mastocytosis in young children and systemic mastocytosis with a more guarded prognosis in a

190 ystemic indolent mastocytosis, 511 (n = 30); systemic mastocytosis with an associated hematologic dis

191 had aggressive systemic mastocytosis, 57 had systemic mastocytosis with an associated hematologic neo

192 f the World Health Organization category of "systemic mastocytosis with associated clonal hematologic

193 consider specific entities, such as SM-MPN, systemic mastocytosis with chronic myelomonocytic leukem

194 olated from a patient with UP and aggressive systemic mastocytosis with massive splenic involvement.

195 monocytic leukemia cases and in 1 child with systemic mastocytosis with MDS.

196 chronic myelomonocytic leukemia, SM-MDS, and systemic mastocytosis with-acute leukemia, rather than t